277 related articles for article (PubMed ID: 21203958)
41. Drug resistance mechanisms and novel drug targets for tuberculosis therapy.
Islam MM; Hameed HMA; Mugweru J; Chhotaray C; Wang C; Tan Y; Liu J; Li X; Tan S; Ojima I; Yew WW; Nuermberger E; Lamichhane G; Zhang T
J Genet Genomics; 2017 Jan; 44(1):21-37. PubMed ID: 28117224
[TBL] [Abstract][Full Text] [Related]
42. Identification of new drug targets and resistance mechanisms in Mycobacterium tuberculosis.
Ioerger TR; O'Malley T; Liao R; Guinn KM; Hickey MJ; Mohaideen N; Murphy KC; Boshoff HI; Mizrahi V; Rubin EJ; Sassetti CM; Barry CE; Sherman DR; Parish T; Sacchettini JC
PLoS One; 2013; 8(9):e75245. PubMed ID: 24086479
[TBL] [Abstract][Full Text] [Related]
43. Novel targets in M. tuberculosis: search for new drugs.
Lamichhane G
Trends Mol Med; 2011 Jan; 17(1):25-33. PubMed ID: 21071272
[TBL] [Abstract][Full Text] [Related]
44. DprE1--from the discovery to the promising tuberculosis drug target.
Mikusová K; Makarov V; Neres J
Curr Pharm Des; 2014; 20(27):4379-403. PubMed ID: 24245764
[TBL] [Abstract][Full Text] [Related]
45.
Sawicki R; Ginalska G
Future Med Chem; 2019 Aug; 11(16):2193-2203. PubMed ID: 31538522
[TBL] [Abstract][Full Text] [Related]
46. Structure-based approaches to drug discovery against tuberculosis.
Holton SJ; Weiss MS; Tucker PA; Wilmanns M
Curr Protein Pept Sci; 2007 Aug; 8(4):365-75. PubMed ID: 17696869
[TBL] [Abstract][Full Text] [Related]
47. Identification of 4-Amino-Thieno[2,3-
Harrison GA; Mayer Bridwell AE; Singh M; Jayaraman K; Weiss LA; Kinsella RL; Aneke JS; Flentie K; Schene ME; Gaggioli M; Solomon SD; Wildman SA; Meyers MJ; Stallings CL
mSphere; 2019 Sep; 4(5):. PubMed ID: 31511370
[TBL] [Abstract][Full Text] [Related]
48. Exploring the Potential Inhibition of Candidate Drug Molecules for Clinical Investigation Based on their Docking or Crystallographic Analyses against
Dey R; Nandi S; Samadder A; Saxena A; Saxena AK
Curr Top Med Chem; 2020; 20(29):2662-2680. PubMed ID: 32885754
[TBL] [Abstract][Full Text] [Related]
49. An
Kumar S; Sahu P; Jena L
Int J Mycobacteriol; 2019; 8(3):252-261. PubMed ID: 31512601
[TBL] [Abstract][Full Text] [Related]
50. The DprE1 enzyme, one of the most vulnerable targets of Mycobacterium tuberculosis.
Riccardi G; Pasca MR; Chiarelli LR; Manina G; Mattevi A; Binda C
Appl Microbiol Biotechnol; 2013 Oct; 97(20):8841-8. PubMed ID: 24037308
[TBL] [Abstract][Full Text] [Related]
51. Virtual screening for the identification of novel inhibitors of Mycobacterium tuberculosis cell wall synthesis: inhibitors targeting RmlB and RmlC.
Ren JX; Qian HL; Huang YX; Zhu NY; Si SY; Xie Y
Comput Biol Med; 2015 Mar; 58():110-7. PubMed ID: 25637777
[TBL] [Abstract][Full Text] [Related]
52. Can mycobacterial genomics generate novel targets as speed-breakers against the race for drug resistance.
Chauhan RS; Chanumolu SK; Rout C; Shrivastava R
Curr Pharm Des; 2014; 20(27):4319-45. PubMed ID: 24245760
[TBL] [Abstract][Full Text] [Related]
53. 2-Carboxyquinoxalines kill mycobacterium tuberculosis through noncovalent inhibition of DprE1.
Neres J; Hartkoorn RC; Chiarelli LR; Gadupudi R; Pasca MR; Mori G; Venturelli A; Savina S; Makarov V; Kolly GS; Molteni E; Binda C; Dhar N; Ferrari S; Brodin P; Delorme V; Landry V; de Jesus Lopes Ribeiro AL; Farina D; Saxena P; Pojer F; Carta A; Luciani R; Porta A; Zanoni G; De Rossi E; Costi MP; Riccardi G; Cole ST
ACS Chem Biol; 2015 Mar; 10(3):705-14. PubMed ID: 25427196
[TBL] [Abstract][Full Text] [Related]
54. Mycobacterium tuberculosis cytochrome P450 enzymes: a cohort of novel TB drug targets.
Hudson SA; McLean KJ; Munro AW; Abell C
Biochem Soc Trans; 2012 Jun; 40(3):573-9. PubMed ID: 22616869
[TBL] [Abstract][Full Text] [Related]
55. Evolution of structural fitness and multifunctional aspects of mycobacterial RND family transporters.
Sandhu P; Akhter Y
Arch Microbiol; 2018 Jan; 200(1):19-31. PubMed ID: 28951954
[TBL] [Abstract][Full Text] [Related]
56. Development of Mycobacterium tuberculosis whole cell screening hits as potential antituberculosis agents.
Cooper CB
J Med Chem; 2013 Oct; 56(20):7755-60. PubMed ID: 23927683
[TBL] [Abstract][Full Text] [Related]
57. Long-range replica exchange molecular dynamics guided drug repurposing against tyrosine kinase PtkA of Mycobacterium tuberculosis.
Nagpal P; Jamal S; Singh H; Ali W; Tanweer S; Sharma R; Grover A; Grover S
Sci Rep; 2020 Mar; 10(1):4413. PubMed ID: 32157138
[TBL] [Abstract][Full Text] [Related]
58. Identification and validation of novel drug targets in Mycobacterium tuberculosis.
Singh V; Mizrahi V
Drug Discov Today; 2017 Mar; 22(3):503-509. PubMed ID: 27649943
[TBL] [Abstract][Full Text] [Related]
59. Drug targets exploited in Mycobacterium tuberculosis: Pitfalls and promises on the horizon.
Bhat ZS; Rather MA; Maqbool M; Ahmad Z
Biomed Pharmacother; 2018 Jul; 103():1733-1747. PubMed ID: 29864964
[TBL] [Abstract][Full Text] [Related]
60. Identification of New MmpL3 Inhibitors by Untargeted and Targeted Mutant Screens Defines MmpL3 Domains with Differential Resistance.
Williams JT; Haiderer ER; Coulson GB; Conner KN; Ellsworth E; Chen C; Alvarez-Cabrera N; Li W; Jackson M; Dick T; Abramovitch RB
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31405862
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
